AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
BRIDGEWATER, N.J., July 27, 2017 -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it will release its second quarter 2017 financial results on Thursday, August 3, 2017.
Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Thursday, August 3, 2017 to discuss the financial results and provide a business update.
Shareholders and other interested parties may participate in the conference call by dialing (844) 707-0669 (domestic) or (703) 639-1223 (international) and referencing conference ID number 53207980. The call will also be webcast live on the internet on the company's website at www.insmed.com.
A replay of the conference call will be accessible approximately two hours after its completion through August 17, 2017 by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international) and referencing conference ID number 53207980. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website at www.insmed.com.
About Insmed
Insmed Incorporated is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. The Company is advancing a global phase 3 clinical study of amikacin liposome inhalation suspension (ALIS) for adult patients with treatment refractory NTM lung disease caused by MAC, a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal. There are currently no approved inhaled products specifically indicated for the treatment of refractory NTM lung infections caused by MAC in the United States or European Union (EU). Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of DPP1 with therapeutic potential in non-CF bronchiectasis, and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension (PAH). For more information, visit www.insmed.com.
"Insmed" is the Company's trademark. All other trademarks, trade names or service marks appearing in this press release are the property of their respective owners.
Investor Contact: Blaine Davis VP, Head of Investor Relations 908-947-2841 [email protected]
